title: Nanoparticles promise new methods to boost oncology outcomes in breast cancer.
abstract: Different types of treatment are available for patients with breast cancer, the most being radiotherapy, chemotherapy, hormonal therapy and combination therapy. Recently, nanoparticles have been emerging as promising agents for cancer therapy and are being investigated as contrast agents, drug carriers, radiosensitizers and also for hyperthermia effects. In this review the focus is on approaches for targeted treatment of breast cancer by combining nanoparticles, chemodrugs and radiation. The availble data suggest the possibility of increased roles for combined therapy, particularly by reducing the dose of each treatment modality, and consequently minimizing related side effects.
authors.affiliation: Department of Medical Physics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran E-mail : milad_hatamian@yahoo.com.
authors.forename: Jalil Pirayesh
authors.initials: JP
authors.lastname: Islamian
authors.forename: Milad
authors.initials: M
authors.lastname: Hatamian
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Rashidi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D003287:Contrast Media; D003847:Deoxyglucose / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004337:Drug Carriers / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D053758:Nanoparticles / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media; D004337:Drug Carriers; D011838:Radiation-Sensitizing Agents; D004317:Doxorubicin; D003847:Deoxyglucose